JP2021522197A5 - - Google Patents
Info
- Publication number
- JP2021522197A5 JP2021522197A5 JP2020557913A JP2020557913A JP2021522197A5 JP 2021522197 A5 JP2021522197 A5 JP 2021522197A5 JP 2020557913 A JP2020557913 A JP 2020557913A JP 2020557913 A JP2020557913 A JP 2020557913A JP 2021522197 A5 JP2021522197 A5 JP 2021522197A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- present
- structure represented
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660208P | 2018-04-19 | 2018-04-19 | |
| US62/660,208 | 2018-04-19 | ||
| PCT/US2019/028168 WO2019204637A1 (en) | 2018-04-19 | 2019-04-18 | 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522197A JP2021522197A (ja) | 2021-08-30 |
| JP2021522197A5 true JP2021522197A5 (enExample) | 2022-04-25 |
| JP7419259B2 JP7419259B2 (ja) | 2024-01-22 |
Family
ID=68239059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557913A Active JP7419259B2 (ja) | 2018-04-19 | 2019-04-18 | 癌の治療のための４’－チオ－ヌクレオチドおよび－ヌクレオシドプロドラッグ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210363170A1 (enExample) |
| EP (2) | EP3781584A4 (enExample) |
| JP (1) | JP7419259B2 (enExample) |
| KR (1) | KR102810546B1 (enExample) |
| CN (1) | CN112513061B (enExample) |
| AU (2) | AU2019256465B2 (enExample) |
| CA (1) | CA3097003A1 (enExample) |
| WO (1) | WO2019204637A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3993806A4 (en) * | 2019-06-05 | 2023-09-13 | Southern Research Institute | Thiarabine- and thiarabine prodrug-based treatments |
| EP4138843A4 (en) * | 2020-04-23 | 2024-07-10 | Southern Research Institute | COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF |
| CN111393314A (zh) * | 2020-04-30 | 2020-07-10 | 安徽红杉生物医药科技有限公司 | 2-烷基-2-氨基丙酸酯盐酸盐的制备方法 |
| CA3186696A1 (en) * | 2020-07-23 | 2022-01-27 | Mark J. Suto | Polymorphs of 5-aza-4'-thio-2-deoxycytidine |
| WO2022031150A1 (ko) * | 2020-08-07 | 2022-02-10 | 주식회사 피노바이오 | 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| WO2023014045A1 (ko) * | 2021-08-02 | 2023-02-09 | 주식회사 피노바이오 | 잘 설계된 다중 표적 억제제로 선정된 4'-티오-5-아자-2'-디옥시사이티딘의 의약 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020322A (en) * | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| US5591722A (en) * | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| CA2338415C (en) * | 1998-07-23 | 2006-10-10 | Southern Research Institute | Preparation of thioarabinofuranosyl compounds and use thereof |
| EP1144373B1 (en) | 1999-01-13 | 2005-10-19 | Genentech, Inc. | Serine protease inhibitors |
| WO2004018494A1 (ja) | 2002-08-22 | 2004-03-04 | Geneticlab Co., Ltd. | ４’−チオヌクレオチド |
| WO2009042767A1 (en) * | 2007-09-26 | 2009-04-02 | Mount Sinai School Of Medicine | Azacytidine analogues and uses thereof |
| US20110218170A1 (en) * | 2010-03-02 | 2011-09-08 | Southern Research Institute | Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents |
| US9156874B2 (en) * | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| KR20170001722A (ko) * | 2012-08-13 | 2017-01-04 | 후지필름 가부시키가이샤 | 1-(2-데옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 합성 중간체, 티오뉴클레오시드의 합성 중간체, 및 그들의 제조법 |
| TWI678373B (zh) | 2014-10-31 | 2019-12-01 | 日商富士軟片股份有限公司 | 硫代核苷衍生物或其鹽及醫藥組合物 |
| CN109553651B (zh) | 2015-04-03 | 2021-08-06 | 四川科伦博泰生物医药股份有限公司 | 4’-硫代核苷的新型化合物及其制备方法、药物组合物和应用 |
| US20160312261A1 (en) * | 2015-04-24 | 2016-10-27 | Plasmia Biotech, S.L. | Enzymatic production of cytosinic nucleoside analogues |
| US10815264B2 (en) * | 2015-05-27 | 2020-10-27 | Southern Research Institute | Nucleotides for the treatment of cancer |
| EP3746452B1 (en) | 2018-02-01 | 2023-09-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides |
| EP4138843A4 (en) * | 2020-04-23 | 2024-07-10 | Southern Research Institute | COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF |
-
2019
- 2019-04-18 WO PCT/US2019/028168 patent/WO2019204637A1/en not_active Ceased
- 2019-04-18 CN CN201980037108.9A patent/CN112513061B/zh active Active
- 2019-04-18 AU AU2019256465A patent/AU2019256465B2/en active Active
- 2019-04-18 KR KR1020207033020A patent/KR102810546B1/ko active Active
- 2019-04-18 EP EP19789422.3A patent/EP3781584A4/en not_active Withdrawn
- 2019-04-18 EP EP22204903.3A patent/EP4209498A1/en active Pending
- 2019-04-18 JP JP2020557913A patent/JP7419259B2/ja active Active
- 2019-04-18 US US17/045,986 patent/US20210363170A1/en not_active Abandoned
- 2019-04-18 CA CA3097003A patent/CA3097003A1/en active Pending
-
2024
- 2024-12-13 AU AU2024278376A patent/AU2024278376A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522197A5 (enExample) | ||
| JP2016502544A5 (enExample) | ||
| CN103282037B (zh) | 抗肿瘤生物碱的联合治疗 | |
| JP2010533206A5 (enExample) | ||
| US8927530B2 (en) | Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent | |
| RU2012100913A (ru) | ПРОТИВООПУХОЛЕВЫЕ КОМБИНАЦИИ С ИНГИБИТОРАМИ mTOR, ГЕРЦЕПТИНОМ И/ИЛИ HKI-272 | |
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| RU2005118417A (ru) | Комбинированное введение индолинона с химиотерапевтическим средством при нарушениях, вызванных клеточной пролиферацией | |
| JP2011520921A (ja) | 抗腫瘍アルカロイドとの併用療法 | |
| HRP20100563T1 (hr) | Derivati dihidropirazolopirimidinona | |
| JP2011522773A5 (enExample) | ||
| JP2012517428A5 (enExample) | ||
| AU2012236142A1 (en) | Methods for treating cancer | |
| JP2015500884A5 (enExample) | ||
| JP2019524852A5 (enExample) | ||
| JP2023524912A5 (enExample) | ||
| RU97118418A (ru) | Фармацевтическая композиция, содержащая n-хлорфенилкарбаматы и n-хлорфенилтиокарбаматы, для ингибирования роста вирусов и злокачественных новообразований | |
| CA2525887A1 (en) | Combined use of ecteinascidin-743 and platinum antineoplastic compounds | |
| RS50692B (sr) | Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera | |
| WO2018054989A4 (en) | Benzoimidazole derivatives as anticancer agents | |
| CA2648945A1 (en) | Chemoprotective methods and compositions | |
| JP7479292B2 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| KR101066804B1 (ko) | 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품 | |
| JP2017509672A5 (enExample) | ||
| JP2023505221A5 (enExample) |